A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

Exclusion Criteria

• •Patients requiring regular maintenance oral steroids for their asthma, or those who are adhering to symbicort SMART single inhaler regime.
• •Pregnancy (where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test \>5mIU/ml), an intention to become pregnant or breast-feeding (lactating).
• •Subjects with active lung disease other than asthma
• •Significant medical (cardiopulmonary, neurological, renal, endocrine, gastrointestinal, psychiatric, hepatic or haematological)co-morbidity which in the view of the investigator could impact on the interpretation of results or participation in the trial, or which is uncontrolled with standard treatment.
• •Current participation in another clinical trial or previous participation within the last 12 weeks.
• •Alcohol or active drug abuse.
• •Ongoing allergen desensitisation therapy
• •Regular use of sedatives, hypnotics, tranquilisers
• •Cancer or previous history of cancer
• •Inability to understand directions for dosing and study assessment.
• •Inability to be contacted in case of emergency.